InterMune Inc., an orphan drug company that specializes in treating fatal scarring of the lungs, is attracting takeover interest from several large pharmaceutical companies, according to Reuter's sources.
Buyer interest has surged in recent weeks after InterMune announced positive late-stage trial results for pirfenidone, a that drug treats idiopathic pulmonary fibrosis.
InterMune has not commented regarding formal offers or bid prices, but current market value is estimated at $2.7 billion.
Read the Reuters press release